nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—penis—rectum cancer	0.147	0.21	CbGeAlD
Lithium—IMPA1—renal system—rectum cancer	0.0375	0.0534	CbGeAlD
Lithium—IMPA2—seminal vesicle—rectum cancer	0.0349	0.0498	CbGeAlD
Lithium—IMPA1—female reproductive system—rectum cancer	0.03	0.0428	CbGeAlD
Lithium—GSK3A—seminal vesicle—rectum cancer	0.0298	0.0424	CbGeAlD
Lithium—GSK3B—epithelium—rectum cancer	0.0297	0.0424	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—rectum cancer	0.0287	0.0409	CbGeAlD
Lithium—IMPA2—renal system—rectum cancer	0.0281	0.0401	CbGeAlD
Lithium—IMPA2—urethra—rectum cancer	0.0276	0.0394	CbGeAlD
Lithium—GSK3B—renal system—rectum cancer	0.0276	0.0393	CbGeAlD
Lithium—IMPA2—mammalian vulva—rectum cancer	0.0263	0.0375	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—rectum cancer	0.0249	0.0355	CbGeAlD
Lithium—GSK3A—renal system—rectum cancer	0.024	0.0342	CbGeAlD
Lithium—GSK3A—urethra—rectum cancer	0.0236	0.0336	CbGeAlD
Lithium—IMPA2—female reproductive system—rectum cancer	0.0225	0.0321	CbGeAlD
Lithium—GSK3A—mammalian vulva—rectum cancer	0.0224	0.032	CbGeAlD
Lithium—GSK3B—female reproductive system—rectum cancer	0.0221	0.0315	CbGeAlD
Lithium—IMPA2—vagina—rectum cancer	0.0204	0.029	CbGeAlD
Lithium—GSK3B—vagina—rectum cancer	0.02	0.0285	CbGeAlD
Lithium—GSK3A—female reproductive system—rectum cancer	0.0192	0.0274	CbGeAlD
Lithium—GSK3A—vagina—rectum cancer	0.0174	0.0248	CbGeAlD
Lithium—IMPA2—lymph node—rectum cancer	0.0132	0.0188	CbGeAlD
Lithium—GSK3B—lymph node—rectum cancer	0.0129	0.0184	CbGeAlD
Lithium—GSK3A—lymph node—rectum cancer	0.0112	0.016	CbGeAlD
Lithium—GRIA3—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—rectum cancer	0.00626	0.0209	CbGpPWpGaD
Lithium—GSK3A—IL-5 Signaling Pathway—KRAS—rectum cancer	0.00538	0.018	CbGpPWpGaD
Lithium—GSK3B—Trk receptor signaling mediated by PI3K and PLC-gamma—NRAS—rectum cancer	0.00502	0.0168	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.00494	0.0165	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—ITGA2—rectum cancer	0.00472	0.0158	CbGpPWpGaD
Lithium—IMPA1—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.00439	0.0147	CbGpPWpGaD
Lithium—GSK3B—Aurora A signaling—TP53—rectum cancer	0.00433	0.0145	CbGpPWpGaD
Lithium—GSK3B—Trk receptor signaling mediated by PI3K and PLC-gamma—KRAS—rectum cancer	0.00432	0.0145	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TYMS—rectum cancer	0.00413	0.0138	CbGpPWpGaD
Lithium—GSK3B—IL-5 Signaling Pathway—KRAS—rectum cancer	0.00397	0.0133	CbGpPWpGaD
Lithium—GSK3B—Trk receptor signaling mediated by PI3K and PLC-gamma—HRAS—rectum cancer	0.00368	0.0123	CbGpPWpGaD
Lithium—GSK3B—LKB1 signaling events—TP53—rectum cancer	0.00333	0.0112	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—KRAS—rectum cancer	0.00313	0.0105	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—ITGA2—rectum cancer	0.00308	0.0103	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TYMS—rectum cancer	0.00293	0.0098	CbGpPWpGaD
Lithium—GSK3B—Copper homeostasis—TP53—rectum cancer	0.00286	0.00958	CbGpPWpGaD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—rectum cancer	0.00278	0.00931	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—rectum cancer	0.00278	0.0093	CbGpPWpGaD
Lithium—GSK3A—Leptin signaling pathway—HRAS—rectum cancer	0.00277	0.00925	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—HRAS—rectum cancer	0.00266	0.00889	CbGpPWpGaD
Lithium—GSK3B—p53 pathway—TP53—rectum cancer	0.00259	0.00866	CbGpPWpGaD
Lithium—GRIA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—rectum cancer	0.00234	0.00784	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—HRAS—rectum cancer	0.00232	0.00776	CbGpPWpGaD
Lithium—GRIA3—BDNF signaling pathway—HRAS—rectum cancer	0.00229	0.00766	CbGpPWpGaD
Lithium—IMPA2—Metabolism—TYMS—rectum cancer	0.00229	0.00765	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—NRAS—rectum cancer	0.00228	0.00763	CbGpPWpGaD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—HRAS—rectum cancer	0.00225	0.00753	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ITGA2—rectum cancer	0.0022	0.00736	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.00218	0.0073	CbGpPWpGaD
Lithium—GSK3B—CDC42 signaling events—HRAS—rectum cancer	0.00216	0.00722	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—NRAS—rectum cancer	0.00215	0.00719	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—NRAS—rectum cancer	0.00207	0.00693	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—NRAS—rectum cancer	0.00205	0.00686	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—rectum cancer	0.00205	0.00686	CbGpPWpGaD
Lithium—GSK3B—Leptin signaling pathway—HRAS—rectum cancer	0.00204	0.00684	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—NRAS—rectum cancer	0.00204	0.00683	CbGpPWpGaD
Lithium—IMPA1—Metabolism—TYMS—rectum cancer	0.00204	0.00682	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—NRAS—rectum cancer	0.00203	0.0068	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—NRAS—rectum cancer	0.00202	0.00676	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00199	0.00667	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—rectum cancer	0.00199	0.00666	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—KRAS—rectum cancer	0.00196	0.00657	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—NRAS—rectum cancer	0.0019	0.00636	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—NRAS—rectum cancer	0.0019	0.00636	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.0019	0.00636	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—NRAS—rectum cancer	0.00188	0.00631	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.00188	0.00629	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.00187	0.00625	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—NRAS—rectum cancer	0.00186	0.00622	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—KRAS—rectum cancer	0.00186	0.00622	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—KRAS—rectum cancer	0.00185	0.00619	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—KRAS—rectum cancer	0.00178	0.00596	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—KRAS—rectum cancer	0.00177	0.00591	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—HRAS—rectum cancer	0.00176	0.00589	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—NRAS—rectum cancer	0.00176	0.00589	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—KRAS—rectum cancer	0.00176	0.00588	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—KRAS—rectum cancer	0.00175	0.00585	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—KRAS—rectum cancer	0.00174	0.00582	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00171	0.00574	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—NRAS—rectum cancer	0.00169	0.00564	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.00168	0.00564	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—rectum cancer	0.00167	0.00559	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—rectum cancer	0.00167	0.00559	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—HRAS—rectum cancer	0.00167	0.00558	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—HRAS—rectum cancer	0.00166	0.00557	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—rectum cancer	0.00165	0.00553	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.00164	0.00548	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—KRAS—rectum cancer	0.00164	0.00548	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—KRAS—rectum cancer	0.00164	0.00548	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—rectum cancer	0.00163	0.00546	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—KRAS—rectum cancer	0.00162	0.00543	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—NRAS—rectum cancer	0.00161	0.0054	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.00161	0.00538	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KRAS—rectum cancer	0.0016	0.00536	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.0016	0.00534	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—NRAS—rectum cancer	0.00159	0.00531	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—rectum cancer	0.00158	0.0053	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—HRAS—rectum cancer	0.00157	0.00526	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—HRAS—rectum cancer	0.00156	0.00522	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	0.00154	0.00515	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—NRAS—rectum cancer	0.00152	0.00507	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—HRAS—rectum cancer	0.00152	0.00507	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—KRAS—rectum cancer	0.00151	0.00507	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—NRAS—rectum cancer	0.00151	0.00505	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—HRAS—rectum cancer	0.00151	0.00505	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—NRAS—rectum cancer	0.0015	0.00502	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—HRAS—rectum cancer	0.0015	0.00502	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—NRAS—rectum cancer	0.00149	0.005	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—HRAS—rectum cancer	0.00149	0.005	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—HRAS—rectum cancer	0.00149	0.00497	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—HRAS—rectum cancer	0.00148	0.00495	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NRAS—rectum cancer	0.00147	0.00493	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00146	0.00488	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KRAS—rectum cancer	0.00145	0.00485	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00145	0.00485	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NRAS—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—NRAS—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—NRAS—rectum cancer	0.00141	0.0047	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—NRAS—rectum cancer	0.00139	0.00466	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—HRAS—rectum cancer	0.00139	0.00466	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—HRAS—rectum cancer	0.00139	0.00466	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.00139	0.00466	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KRAS—rectum cancer	0.00139	0.00464	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—NRAS—rectum cancer	0.00138	0.00462	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—HRAS—rectum cancer	0.00138	0.00461	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—NRAS—rectum cancer	0.00137	0.0046	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	0.00137	0.00458	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.00137	0.00457	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KRAS—rectum cancer	0.00137	0.00457	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—HRAS—rectum cancer	0.00136	0.00455	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—HRAS—rectum cancer	0.00135	0.00451	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KRAS—rectum cancer	0.0013	0.00437	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NRAS—rectum cancer	0.0013	0.00435	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KRAS—rectum cancer	0.0013	0.00434	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NRAS—rectum cancer	0.0013	0.00433	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KRAS—rectum cancer	0.00129	0.00432	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—rectum cancer	0.00129	0.00431	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KRAS—rectum cancer	0.00129	0.0043	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—rectum cancer	0.00127	0.00424	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—rectum cancer	0.00124	0.00416	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—rectum cancer	0.00123	0.00413	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.00123	0.00412	CbGpPWpGaD
Lithium—GSK3B—BDNF signaling pathway—HRAS—rectum cancer	0.00121	0.00406	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—rectum cancer	0.00121	0.00405	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—rectum cancer	0.00121	0.00405	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—rectum cancer	0.00121	0.00405	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KRAS—rectum cancer	0.0012	0.00401	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—rectum cancer	0.00119	0.00398	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—rectum cancer	0.00118	0.00396	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—rectum cancer	0.00118	0.00395	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—HRAS—rectum cancer	0.00116	0.00389	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KRAS—rectum cancer	0.00112	0.00375	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—rectum cancer	0.00112	0.00373	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—rectum cancer	0.00111	0.00373	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—rectum cancer	0.00111	0.00371	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—rectum cancer	0.0011	0.00369	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—rectum cancer	0.0011	0.00367	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—rectum cancer	0.00109	0.00366	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—rectum cancer	0.00108	0.0036	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—rectum cancer	0.00107	0.00358	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—rectum cancer	0.00103	0.00344	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—rectum cancer	0.00103	0.00344	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—rectum cancer	0.00103	0.00344	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—rectum cancer	0.00102	0.00341	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—rectum cancer	0.00101	0.00338	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—rectum cancer	0.00101	0.00336	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—rectum cancer	0.000971	0.00325	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—rectum cancer	0.000971	0.00325	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—rectum cancer	0.000957	0.0032	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—rectum cancer	0.000951	0.00318	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—rectum cancer	0.000948	0.00317	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—rectum cancer	0.000911	0.00305	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—rectum cancer	0.000866	0.0029	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—rectum cancer	0.000824	0.00276	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—rectum cancer	0.000781	0.00261	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—rectum cancer	0.000746	0.00249	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—rectum cancer	0.000739	0.00247	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—rectum cancer	0.00071	0.00237	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—rectum cancer	0.0007	0.00234	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—rectum cancer	0.000636	0.00213	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—rectum cancer	0.000634	0.00212	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—rectum cancer	0.000618	0.00207	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—rectum cancer	0.000611	0.00204	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—rectum cancer	0.000546	0.00183	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—rectum cancer	0.000541	0.00181	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—rectum cancer	0.000532	0.00178	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—rectum cancer	0.000524	0.00175	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—rectum cancer	0.000519	0.00174	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—rectum cancer	0.00047	0.00157	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—rectum cancer	0.000452	0.00151	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—rectum cancer	0.000451	0.00151	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—rectum cancer	0.00043	0.00144	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—rectum cancer	0.000399	0.00134	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—rectum cancer	0.000397	0.00133	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—rectum cancer	0.000384	0.00128	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—rectum cancer	0.00037	0.00124	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—rectum cancer	0.000342	0.00114	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—rectum cancer	0.000318	0.00106	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—rectum cancer	0.000315	0.00105	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—rectum cancer	0.000294	0.000982	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—rectum cancer	0.000291	0.000973	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—rectum cancer	0.000278	0.000931	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—rectum cancer	0.000274	0.000916	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—rectum cancer	0.000253	0.000846	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—rectum cancer	0.000239	0.000801	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—rectum cancer	0.000233	0.000778	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—rectum cancer	0.000215	0.000719	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—rectum cancer	0.000213	0.000712	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—rectum cancer	0.000206	0.000688	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—rectum cancer	0.000204	0.000681	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—rectum cancer	0.000177	0.000592	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—rectum cancer	0.000157	0.000526	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—rectum cancer	0.00015	0.000503	CbGpPWpGaD
